Skip to content

Study · Not a test of the peptide alone · 2018

5 results

A dimeric thymosin beta 4 with novel bio-activity protects post-ischemic cardiac function by accelerating vascular endothelial cell proliferation.

Hao Q, He L, Zhou J, Yuan Y, Ma X, Pang Z, Li W, Zhang Y, Zhang W, Zhang C, Li M

International journal of cardiology14 Mar 2018Cited by 6 (Europe PMC)

PMID29550018 (opens in a new tab)DOI10.1016/j.ijcard.2018.03.052 (opens in a new tab)PepBankPUB-29550018
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In mice with myocardial infarction, the cardioprotective effect of dimeric Tβ4 was significantly higher than that of wild-type Tβ4.

    In plain wordsIn mice with heart attack, a dimer form of Tβ4 protected the heart more than normal Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCardioprotective effect on echocardiography
    Study

    mousen: not reported in source

    myocardial infarction mice
    Comparator
    Wild-type Tβ4
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Echocardiography measurements showed that the cardioprotective effect of DTβ4 in myocardial infarction mice was significantly higher than that of wild-type Tβ4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In vitro, the enhanced cardioprotection of dimeric Tβ4 was largely due to increased stimulation of angiogenesis.

    In plain wordsIn lab tests, the dimer form of Tβ4 protected the heart mainly by stimulating more new blood vessel growth.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAngiogenesis stimulation
    Study

    n: not reported in source

    in vitro angiogenesis analyses
    Comparator
    Wild-type Tβ4
    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    Corresponding in vitro analyses demonstrated that the enhanced cardioprotection provided by DTβ4 was largely due to increased stimulation of angiogenesis.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In vascular endothelial cells, the enhanced angiogenic activity of dimeric Tβ4 depended on MALAT1-induced proliferation.

    In plain wordsIn cells, the dimer form of Tβ4 stimulated blood vessel cell growth through MALAT1.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseMALAT1-dependent endothelial cell proliferation
    Study

    n: not reported in source

    vascular endothelial cells
    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    Transcriptome deep sequencing (RNA-seq), BrdU incorporation assays, flow cytometry analysis and RNA interference demonstrated that the enhanced angiogenic activity of DTβ4 depended on MALAT1 (metastasis-associated lung adenocarcinoma transcript 1)-induced proliferation of vascular endothelial cells,…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In cells, dimeric Tβ4 enhanced MALAT1 transcription by inhibiting the degradation of PROX1.

    In plain wordsIn cells, the dimer form of Tβ4 increased MALAT1 activity by slowing the breakdown of the PROX1 protein.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreasePROX1 degradation and MALAT1 transcription
    Study

    n: not reported in source

    vascular endothelial cells
    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    Moreover, transcription factor activation screening, luciferase promoter reporter assay and immunoprecipitation assay demonstrated that DTβ4 enhanced MALAT1 transcription by inhibiting the degradation of prospero-related homeobox 1 (PROX1).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In vitro, the enhanced pro-angiogenic activity of dimeric Tβ4 was independent of protein half-life and of the known downstream pathways of wild-type Tβ4.

    In plain wordsIn lab tests, the dimer form of Tβ4 boosted blood vessel growth without relying on its half-life or on known Tβ4 pathways.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableHalf-life and known downstream pathways of dimeric Tβ4
    Study

    n: not reported in source

    in vitro analyses
    Comparator
    Wild-type Tβ4
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    HPLC analysis, western blotting and qRT-PCR indicated that the enhanced pro-angiogenesis activity of DTβ4 was independent of the protein half-life and the known downstream pathways of wild-type Tβ4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.